Cytokines

Recombinant Human CCL28 protein is a valuable research tool for scientists investigating the intricacies of the immune system. This C-C motif chemokine 28, also known as CCL28 and SCYA28, is produced in E. coli and encompasses the 20-127aa expression region of the full-length mature protein. The tag-free protein is provided in a lyophilized powder format, facilitating effortless reconstitution with sterile water or buffer to suit a wide range of experimental conditions.

We are dedicated to delivering high-quality products. Our Recombinant Human CCL28 protein exhibits a purity exceeding 97%, as confirmed by SDS-PAGE and HPLC analysis. Furthermore, endotoxin levels are rigorously controlled below 1.0 EU/µg, as determined by the LAL method. The protein exhibits full biological activity in a chemotaxis bioassay using human lymphocytes, with an effective concentration range of 1.0-10.0 ng/ml.

The role of CCL28 in immune regulation has been extensively studied. Hieshima *et al*. (2003)^[1] first identified CCL28 as a chemokine that binds to CCR10 and attracts IgA-producing plasma cells to mucosal tissues. Subsequent research by Pan *et al*. (2006)^[2] highlighted the involvement of CCL28 in the pathogenesis of inflammatory bowel disease. More recently, Meijerink *et al*. (2018)^[3] explored the potential of CCL28 as a therapeutic target for colorectal cancer. These studies underscore the significance of CCL28 in the immune system and its potential as a therapeutic target for immune-related diseases.

References:
1. Hieshima K, *et al*. CCL28 has dual roles in mucosal immunity as a chemokine with broad-spectrum antimicrobial activity. J Immunol. 2003;170(3): 1452-61.
2. Pan J, *et al*. A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J Immunol. 2000;165(6): 2943-9.
3. Meijerink M, *et al*. The chemokine CCL28 and its receptor CCR10: A promising therapeutic target in colorectal cancer. J Pathol. 2018;244(4): 393-404.